Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 2

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 2
---
 offer or sale is not permitted.

<div align='center'>SUBJECT TO COMPLETION, DATED SEPTEMBER 2, 2025</div>

PRELIMINARY PROSPECTUS

<div align='center'>Indaptus Therapeutics, Inc.

Up to 781,250 Shares of Common Stock

Up to 781,250 Series A Common Warrants to Purchase up to 781,250 Shares of Common Stock

Up to 781,250 Series B Common Warrants to Purchase up to 781,250 Shares of Common Stock

Up to 781,250 Pre-funded Warrants to Purchase up to 781,250 Shares of Common Stock

Up to 46,875 Placement Agent Warrants to Purchase up to 46,875 Shares of Common Stock

Up to 2,390,625 Shares of Common Stock Issuable Upon Exercise of the Series A Common Warrants, Series B Common Warrants, Pre-funded Warrants and Placement Agent Warrants</div>

We are offering in a best-efforts
offering up to 781,250 shares of common stock, par value $0.01 per share of Indaptus Therapeutics, Inc., a Delaware Company (“Indaptus”,
the “Company”, “our company”, “we” or “us”), together with up to 781,250 series A
common warrants, or the Series A common warrants, to purchase up to 781,250 shares of common stock and 781,250 series B common
warrants, or the Series B common warrants and together with the Series A common warrants, the common warrants, to purchase up to 781,250
shares of common stock at an assumed combined public offering price of $6.40 per share and common warrants pursuant to
this prospectus, which was the closing price of our shares of common stock on the Nasdaq Capital Market (“Nasdaq”) on August
27, 2025. The shares of common stock and common warrants will be sold in a fixed combination, with each share accompanied by a
Series A common warrant and a Series B common warrant, each warrant to purchase one share of common stock.

We are also offering to those purchasers, if any, whose purchase of our shares of common stock in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock immediately